Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mingjia Li

Showing results (71-80 of 91) with videos related to

Pageof 10
Sort By:
BMC Cancer|May 8, 2020
Inferring the role of the microbiome on survival in patients treated with immune checkpoint inhibitors: causal modeling, timing, and classes of concomitant medicationsDaniel Spakowicz, Rebecca Hoyd, Mitchell Muniak, et al.
Lung Cancer (Amsterdam, Netherlands)|November 15, 2025
Impact of immune-related and non-immune related hospital admissions on survival of patients with non-small cell lung cancer receiving first-line immunotherapyAdam Khorasanchi, Mingjia Li, Songzhu Zhao, et al.
Cancer Investigation|October 10, 2025
Early Changes in Lymphocyte/Monocyte Ratio on Treatment as a Prognostic Marker to Predict Overall Survival in Patients with Advanced Cancer Treated with Immune Checkpoint InhibitorsSandip H Patel, Songzhu Zhao, Mingjia Li, et al.
Cancer Immunology, Immunotherapy : CII|February 16, 2023
Mean platelet volume, thrombocytosis, and survival in non-small cell lung cancer patients treated with first-line pembrolizumab alone or with chemotherapyMingjia Li, Songzhu Zhao, Gabrielle Lopez, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|November 7, 2023
Association Between Pretreatment Chest Imaging and Immune Checkpoint Inhibitor Pneumonitis Among Patients With Lung CancerAlexander Wong, Maria Riley, Songzhu Zhao, et al.
Journal of Cancer|June 22, 2026
Association between obesity, sex, medical comorbidities, and survival in cancer patients treated with immune checkpoint inhibitorsMingjia Li, Daniel J Spakowicz, Songzhu Zhao, et al.
Clinical Lung Cancer|February 8, 2022
Serum Albumin: Early Prognostic Marker of Benefit for Immune Checkpoint Inhibitor Monotherapy But Not ChemoimmunotherapyYizhen Guo, Lai Wei, Sandip H Patel, et al.
Cancer Immunology, Immunotherapy : CII|March 9, 2026
Impact of proton pump inhibitors on immunotherapy is modulated by prior chemotherapy and linked to gut microbiome-immune cell signaturesAnnastasia Petouhoff, Ryan Hicks, Marium Husain, et al.
Urologic Oncology|November 28, 2022
A multicenter study assessing survival in patients with metastatic renal cell carcinoma receiving immune checkpoint inhibitor therapy with and without cytoreductive nephrectomyEvan E Gross, Mingjia Li, Ming Yin, et al.
Journal of Medical Internet Research|March 17, 2023
Artificial Intelligence-Based Psoriasis Severity Assessment: Real-world Study and ApplicationKai Huang, Xian Wu, Yixin Li, et al.
Pageof 10

Showing results (71-80 of 91) with videos related to

Sort By:
Pageof 10
BMC Cancer|May 8, 2020
Inferring the role of the microbiome on survival in patients treated with immune checkpoint inhibitors: causal modeling, timing, and classes of concomitant medicationsDaniel Spakowicz, Rebecca Hoyd, Mitchell Muniak, et al.
Lung Cancer (Amsterdam, Netherlands)|November 15, 2025
Impact of immune-related and non-immune related hospital admissions on survival of patients with non-small cell lung cancer receiving first-line immunotherapyAdam Khorasanchi, Mingjia Li, Songzhu Zhao, et al.
Cancer Investigation|October 10, 2025
Early Changes in Lymphocyte/Monocyte Ratio on Treatment as a Prognostic Marker to Predict Overall Survival in Patients with Advanced Cancer Treated with Immune Checkpoint InhibitorsSandip H Patel, Songzhu Zhao, Mingjia Li, et al.
Cancer Immunology, Immunotherapy : CII|February 16, 2023
Mean platelet volume, thrombocytosis, and survival in non-small cell lung cancer patients treated with first-line pembrolizumab alone or with chemotherapyMingjia Li, Songzhu Zhao, Gabrielle Lopez, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|November 7, 2023
Association Between Pretreatment Chest Imaging and Immune Checkpoint Inhibitor Pneumonitis Among Patients With Lung CancerAlexander Wong, Maria Riley, Songzhu Zhao, et al.
Journal of Cancer|June 22, 2026
Association between obesity, sex, medical comorbidities, and survival in cancer patients treated with immune checkpoint inhibitorsMingjia Li, Daniel J Spakowicz, Songzhu Zhao, et al.
Clinical Lung Cancer|February 8, 2022
Serum Albumin: Early Prognostic Marker of Benefit for Immune Checkpoint Inhibitor Monotherapy But Not ChemoimmunotherapyYizhen Guo, Lai Wei, Sandip H Patel, et al.
Cancer Immunology, Immunotherapy : CII|March 9, 2026
Impact of proton pump inhibitors on immunotherapy is modulated by prior chemotherapy and linked to gut microbiome-immune cell signaturesAnnastasia Petouhoff, Ryan Hicks, Marium Husain, et al.
Urologic Oncology|November 28, 2022
A multicenter study assessing survival in patients with metastatic renal cell carcinoma receiving immune checkpoint inhibitor therapy with and without cytoreductive nephrectomyEvan E Gross, Mingjia Li, Ming Yin, et al.
Journal of Medical Internet Research|March 17, 2023
Artificial Intelligence-Based Psoriasis Severity Assessment: Real-world Study and ApplicationKai Huang, Xian Wu, Yixin Li, et al.
Pageof 10